about
Diet and Alzheimer’s disease risk factors or prevention: the current evidenceGlobal, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transitionThe role of early life environmental risk factors in Parkinson disease: what is the evidence?Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's DiseaseUltrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the LiteratureNonsteroidal anti-inflammatory drugs and the incidence of Parkinson diseaseMeeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015The changing picture of amyotrophic lateral sclerosis: lessons from European registers.Current Issues in Randomized Clinical Trials of Neurodegenerative Disorders at Enrolment and Reporting: Diagnosis, Recruitment, Representativeness of Patients, Ethnicity, and Quality of Reporting.General Overview, Conclusions, and Future Directions.Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.Association of smoking with amyotrophic lateral sclerosis risk and survival in men and women: a prospective studyCan mortality data be used to estimate amyotrophic lateral sclerosis incidence?Incidence of amyotrophic lateral sclerosis in Europe.Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies.Frontotemporal dementia and its subtypes: a genome-wide association study.Nutrition, frailty, and Alzheimer's disease.Standards for epidemiologic studies and surveillance of epilepsy.Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study.Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis.Migraine and risk of cardiovascular disease in women.Cortical thinning and clinical heterogeneity in amyotrophic lateral sclerosis.Depression and incident stroke in womenEmployment of higher doses of botulinum toxin type A to reduce spasticity after stroke.Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanisms.Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72.Frailty syndrome and all-cause mortality in demented patients: the Italian Longitudinal Study on Aging.Smoking and risk of amyotrophic lateral sclerosis: a pooled analysis of 5 prospective cohorts.Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study.Dietary flavonoids and risk of stroke in women.C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population.Frontal assessment battery for detecting executive dysfunction in amyotrophic lateral sclerosis without dementia: a retrospective observational studyHospitalizations due to respiratory failure in patients with Amyotrophic Lateral Sclerosis and their impact on survival: a population-based cohort studyA long diagnostic delay in patients with Hereditary Haemorrhagic Telangiectasia: a questionnaire-based retrospective studyMethodologic issues in studies of mortality following epilepsy: measures, types of studies, sources of cases, cohort effects, and competing risks.Mortality after a first episode of status epilepticus in the United States and Europe.COGNITIVE-HD study: protocol of an observational study of neurocognitive functioning and association with clinical outcomes in adults with end-stage kidney disease treated with haemodialysis.Prospective study of dietary pattern and risk of Parkinson disease.
P50
Q22241476-1E76B49F-DAF7-437F-AE7F-9FB972BA9777Q24170269-10392929-A0B9-4A4A-9CF0-560D6B03E3D4Q24815642-E41DC9AB-5718-4977-A58C-1481090A87F3Q26746902-32AC4F07-41E4-4A8A-A974-442077D8A03BQ26798457-249681E4-B2E1-4DE6-88F6-85266E36AD4AQ28196448-A6454AA5-7FA2-4226-A57F-AFAB7232DF1CQ28387116-59E6234A-F010-44FF-B85E-6419C84F2426Q28391248-D8D0A852-BD44-4754-A477-288C209AB0A8Q30235329-9594F2DF-91F4-4353-A87D-3ABA6F9F4C00Q30248763-8AE8FB24-1C63-4F82-8382-792BEECB8FA8Q30248770-9A1E1C20-DE89-4098-8F30-4B6622EBE4AEQ30358426-328391BC-F7C1-4E09-A8F9-0F296B4734FEQ30410700-7327E707-3942-4B30-9457-5AE5A7F50026Q33523900-245ED4FC-6DC4-458B-AE54-412053509B74Q33751002-6C1FCD99-CE29-4797-B8A8-1B718A34D94EQ33774202-A672C599-0599-4FA8-8662-A484B23B2642Q33824784-3E231366-97A5-4B6A-8CF5-60CEAA643745Q33955007-FEC5395F-47B3-4886-A331-3DEF6457F60EQ34085112-D2803E0A-6A67-4689-9AC9-FEF9991439B0Q34214261-5B73FC53-2322-4A22-AB43-CFA5D3E59400Q34505182-227FA69E-5C82-4E42-B299-7A08CAA05E82Q34508879-5F49CBEC-5040-47A6-84B4-52112862DA36Q34569226-CCBC0C3A-9F8D-47F1-A959-2E99955B9B12Q35053698-60DB841C-8690-48A7-9262-3B6367099E0AQ35242408-5184358C-1189-4463-9149-0F179AF11F2EQ35561848-D7BD10A8-4C3C-4A14-ACAA-CD71647BB4E9Q35698827-D978E9A2-3031-4BB0-BC2C-7E6C292DB8B3Q35776923-7DDDBE44-8357-4A53-80D0-FCE79780B635Q35853672-86503C25-E91F-498B-B7D3-959C27607793Q35869201-72374A47-0B0F-4FD3-A0D3-0C17DC4A7C7BQ35891811-02CD1561-8C9C-4EB2-9F79-A2800B1CD5BEQ35989900-9A1D8167-4AAE-4F54-B70C-5A10EC356CE6Q36024669-83E4CEEA-A1FB-4458-AC33-D801AEBB4F68Q36039036-2D2632EE-0C38-4EE2-AF7D-DFE47558B02BQ36181514-B5853D2B-BA7F-4132-9A12-D6ED11B5BE1BQ36281641-5EC65F50-AA8A-41A1-BDE5-26DF183FECD4Q36360470-4CDDAACE-4299-4385-90EB-8E983C555CEDQ36360497-944C0C0A-EED4-4974-8851-0A0C1A9879FCQ36374037-E26C7089-363F-43CF-A591-56B64C8234FDQ36426202-C7A1DAC4-285F-4EE4-BC9B-D19C4B68D45B
P50
description
onderzoeker
@nl
name
Giancarlo Logroscino
@ast
Giancarlo Logroscino
@en
Giancarlo Logroscino
@es
Giancarlo Logroscino
@nl
type
label
Giancarlo Logroscino
@ast
Giancarlo Logroscino
@en
Giancarlo Logroscino
@es
Giancarlo Logroscino
@nl
prefLabel
Giancarlo Logroscino
@ast
Giancarlo Logroscino
@en
Giancarlo Logroscino
@es
Giancarlo Logroscino
@nl